Mutation Analysis of Nine Chordoma Specimens by Targeted Next-Generation Cancer Panel Sequencing
Open Access
- 1 January 2015
- journal article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 6 (10), 984-989
- https://doi.org/10.7150/jca.11371
Abstract
Background: Chordoma is a rare primary malignant bone tumour. Treatment options are mainly restricted to surgical excision, since chordomas are largely resistant to conventional ionising radiation and chemotherapy. Thus, there is a strong need to gain more thorough insights into the molecular biology and genetics of chordoma to allow for the development of new therapeutic options. We performed an ultra-deep sequencing analysis to find novel mutations in cancer associated genes in chordomas to date unseen with Sanger sequencing.Keywords
This publication has 26 references indexed in Scilit:
- Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1PLOS ONE, 2014
- Durable stabilization of three chordoma cases by bevacizumab and erlotinibActa Oncologica, 2014
- Expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and matrix metalloproteinase-2 in sacral chordomasOncology Letters, 2012
- Chordoma: current concepts, management, and future directionsThe Lancet Oncology, 2012
- Response to imatinib plus sirolimus in advanced chordomaAnnals of Oncology, 2009
- Chordoma: The Nonsarcoma Primary Bone TumorThe Oncologist, 2007
- ChordomaCurrent Opinion in Oncology, 2007
- Incipient chordoma: a report of two cases of early-stage chordoma arising from benign notochordal cell tumorsLaboratory Investigation, 2005
- Chordoma: incidence and survival patterns in the United States, 1973–1995Cancer Causes & Control, 2001
- Loss of heterozygosity in the retinoblastoma tumor suppressor gene in skull base chordomas and chondrosarcomasSurgical Neurology, 1997